NCT02015104: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 9 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02015104 |
|---|---|
| Title | A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 18, 2013 |
| Completion date | Sept. 18, 2018 |
| Required reporting date | Sept. 18, 2019, midnight |
| Actual reporting date | Sept. 27, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 9 |